ࡱ> _ BUbjbj,E,E ?\N/N/    8BV l     RRRprrrrrr$3D9RRRRR  HR  pRp K}k F\0wfXw&wxRRRRRRRRRRRRRRwRRRRRRRRR : Appendix Table A4. Efficacy of all available interventions according to treatment-level Bayesian network analysis Gef1.02 (0.48-2.36)1.07 (0.26-4.64)2.01 (0.48-11.80)0.93 (0.45-2.36)0.63 (0.20-1.98)NA1.18 (0.24-6.17)4.73 (0.64-36.30)0.74 (0.17-3.39)1.42 (0.34-6.37)NA0.72 (0.11-4.89)0.61 (0.10-3.98)0.75 (0.18-3.28)NANA1.03 (0.44-2.57)2.75 (0.47-15.90)0.35 (0.09-1.39)1.14 (0.18-7.51)1.22 (0.52-3.92)1.13 (0.68-1.90)Erlo1.04 (0.25-4.11)1.96 (0.41-12.40)0.91 (0.37-2.44)0.62 (0.15-2.37)NA1.15 (0.28-4.68)4.59 (0.71-29.30)0.72 (0.20-2.60)1.39 (0.40-4.78)NA0.70 (0.11-4.45)0.60 (0.10-3.55)0.74 (0.18-2.88)NANA1.01 (0.45-2.18)2.67 (0.53-12.70)0.34 (0.07-1.60)1.11 (0.18-6.77)1.19 (0.41-4.42)1.02 (0.41-2.56)0.90 (0.40-2.11)Ico1.88 (0.27-18.40)0.87 (0.19-4.65)0.60 (0.09-3.67)NA1.11 (0.15-8.20)4.43 (0.45-44.50)0.69 (0.11-4.68)1.33 (0.21-8.99)NA0.68 (0.08-5.33)0.58 (0.08-4.29)0.71 (0.14-3.78)NANA0.97 (0.30-3.17)2.57 (0.32-21.00)0.33 (0.04-2.34)1.07 (0.34-3.50)1.14 (0.24-7.45)1.41 (0.69-2.76)1.24 (0.55-2.73)1.39 (0.45-3.98)Afa0.47 (0.09-2.02)0.32 (0.04-1.84)NA0.58 (0.06-4.74)2.32 (0.17-25.30)0.37 (0.04-2.67)0.71 (0.08-4.96)NA0.36 (0.03-3.71)0.31 (0.02-2.95)0.38 (0.04-2.70)NANA0.52 (0.07-2.60)1.34 (0.12-12.10)0.17 (0.02-1.22)0.57 (0.04-5.63)0.61 (0.17-2.06)1.26 (0.60-2.50)1.11 (0.51-2.34)1.24 (0.40-3.55)0.90 (0.35-2.26)Dac0.68 (0.15-2.52)NA1.26 (0.22-6.71)4.99 (0.60-38.20)0.79 (0.15-3.74)1.52 (0.30-6.85)NA0.78 (0.10-5.47)0.67 (0.09-4.22)0.82 (0.15-3.68)NANA1.12 (0.34-3.13)2.92 (0.44-17.50)0.37 (0.07-1.78)1.23 (0.16-8.25)1.30 (0.55-3.66)1.81 (0.87-3.69)1.59 (0.74-3.50)1.78 (0.61-5.01)1.29 (0.50-3.37)1.43 (0.55-3.93)OsiNA1.88 (0.28-14.10)7.52 (0.81-78.40)1.16 (0.19-7.89)2.24 (0.37-15.50)NA1.13 (0.13-10.70)0.97 (0.12-8.21)1.20 (0.20-7.81)NANA1.63 (0.40-7.20)4.25 (0.52-36.80)0.55 (0.09-3.18)1.81 (0.22-16.90)1.91 (0.49-10.10)0.62 (0.21-1.94)0.55 (0.16-1.90)0.61 (0.14-2.58)0.44 (0.12-1.72)0.49 (0.14-1.93)0.34 (0.09-1.31)NaqNANANANANANANANANANANANANANANA1.97 (0.77-5.05)1.74 (0.78-3.88)1.94 (0.61-6.06)1.41 (0.46-4.43)1.57 (0.54-4.86)1.09 (0.35-3.32)3.15 (0.73-13.60)Erlo+Bev3.97 (0.38-40.90)0.63 (0.10-4.24)1.21 (0.19-8.00)NA0.62 (0.06-6.04)0.52 (0.05-5.00)0.64 (0.09-4.58)NANA0.88 (0.17-4.35)2.32 (0.27-18.60)0.30 (0.03-2.37)0.97 (0.10-9.65)1.04 (0.18-7.22)0.98 (0.23-4.19)0.87 (0.22-3.40)0.96 (0.19-4.68)0.70 (0.15-3.40)0.78 (0.17-3.79)0.54 (0.11-2.62)1.57 (0.25-9.87)0.50 (0.10-2.41)Ona+Erlo0.16 (0.02-1.50)0.30 (0.03-2.76)NA0.15 (0.01-1.99)0.13 (0.01-1.62)0.16 (0.02-1.55)NANA0.22 (0.03-1.64)0.58 (0.05-6.60)0.07 (0.01-0.83)0.24 (0.02-3.19)0.26 (0.03-2.62)NANANANANANANANANAErlo+Tiv1.93 (0.33-11.90)NA0.98 (0.10-9.49)0.84 (0.09-7.29)1.02 (0.15-6.61)NANA1.40 (0.31-6.23)3.71 (0.48-28.80)0.47 (0.06-3.51)1.55 (0.17-14.30)1.65 (0.32-10.70)0.95 (0.24-3.58)0.84 (0.24-2.84)0.93 (0.20-4.08)0.68 (0.16-3.01)0.75 (0.18-3.25)0.53 (0.12-2.26)1.52 (0.27-8.65)0.48 (0.11-2.06)0.97 (0.15-6.08)NASun+ErloNA0.50 (0.05-4.61)0.44 (0.05-3.63)0.54 (0.08-3.36)NANA0.73 (0.16-3.14)1.93 (0.26-13.90)0.24 (0.03-1.74)0.80 (0.09-6.93)0.86 (0.17-5.25)1.47 (0.48-4.51)1.30 (0.39-4.45)1.44 (0.35-5.96)1.05 (0.29-4.00)1.17 (0.33-4.47)0.82 (0.22-3.08)2.36 (0.49-11.50)0.75 (0.18-3.24)1.50 (0.24-9.40)NA1.55 (0.28-9.04)Gef+PemeNANANANANANANANANANA1.00 (0.19-5.43)0.88 (0.17-4.80)0.98 (0.16-5.98)0.71 (0.13-4.35)0.79 (0.14-4.97)0.56 (0.10-3.22)0.51 (0.08-3.32)1.02 (0.12-8.97)1.05 (0.13-8.83)NA0.68 (0.09-5.11)1.62 (0.32-7.91)Cil+Cet+Plat0.85 (0.17-4.48)1.05 (0.32-3.61)NANA1.44 (0.27-7.87)3.79 (0.34-41.80)0.48 (0.05-4.92)1.57 (0.15-17.20)1.69 (0.23-16.20)0.62 (0.13-3.18)0.55 (0.11-2.75)0.61 (0.11-3.44)0.44 (0.08-2.51)0.49 (0.09-2.87)0.34 (0.07-1.85)1.00 (0.15-6.96)0.31 (0.05-1.93)0.63 (0.08-5.21)NA0.65 (0.09-5.02)0.42 (0.06-2.97)0.62 (0.13-3.11)Cet+Bev+Plat1.23 (0.41-3.69)NANA1.68 (0.33-3.69)4.39 (0.43-47.40)0.56 (0.06-5.15)1.85 (0.18-18.60)1.95 (0.30-17.40)0.57 (0.18-1.88)0.50 (0.16-1.67)0.56 (0.15-2.18)0.41 (0.11-1.57)0.45 (0.12-1.82)0.32 (0.09-1.15)0.91 (0.18-4.63)0.29 (0.07-1.23)0.58 (0.10-3.53)NA0.60 (0.11-3.46)0.39 (0.08-1.97)0.57 (0.17-1.90)0.92 (0.32-2.70)Cet+PlatNANA1.37 (0.44-4.31)3.59 (0.46-28.50)0.46 (0.06-3.22)1.49 (0.20-11.60)1.60 (0.33-10.30)1.97 (0.54-7.15)1.74 (0.48-6.43)1.93 (0.44-8.39)1.40 (0.35-5.93)1.56 (0.38-6.79)1.09 (0.27-4.44)3.15 (0.57-17.80)1.00 (0.22-4.56)2.00 (0.31-13.40)NA2.06 (0.35-12.90)1.33 (0.24-7.36)1.97 (0.26-14.10)3.17 (0.45-21.80)3.44 (0.68-17.10)Erlo+PlatNANANANANANA0.86 (0.24-3.09)0.76 (0.22-2.75)0.84 (0.20-3.67)0.61 (0.15-2.54)0.68 (0.17-2.94)0.48 (0.12-1.88)1.37 (0.25-7.60)0.43 (0.10-1.99)0.87 (0.14-5.74)NA0.91 (0.16-5.46)0.58 (0.11-3.13)1.38 (0.20-9.63)1.50 (0.30-7.67)0.44 (0.08-2.37)1.74 (0.53-5.72)Mot+PlatNANANANANA0.49 (0.31-0.80)0.44 (0.28-0.71)0.48 (0.21-1.11)0.35 (0.17-0.76)0.39 (0.19-0.89)0.27 (0.14-0.55)0.79 (0.24-2.69)0.25 (0.10-0.63)0.50 (0.12-2.15)NA0.52 (0.14-1.99)0.33 (0.10-1.10)0.49 (0.10-2.45)0.79 (0.17-3.62)0.86 (0.29-2.55)0.25 (0.08-0.85)0.57 (0.18-1.88)Plat2.64 (0.45-15.20)0.34 (0.07-1.65)1.10 (0.21-5.77)1.18 (0.37-4.82)0.94 (0.25-3.56)0.82 (0.24-2.79)0.91 (0.21-3.96)0.67 (0.16-2.91)0.74 (0.18-3.21)0.51 (0.12-2.21)1.49 (0.26-8.52)0.47 (0.11-2.03)0.95 (0.15-5.96)NA0.98 (0.17-5.66)0.63 (0.11-3.59)0.93 (0.12-7.40)1.50 (0.20-11.10)1.64 (0.29-8.81)0.48 (0.08-2.84)1.08 (0.18-6.25)1.89 (0.51-6.92)Doc0.13 (0.01-1.19)0.42 (0.04-4.59)0.45 (0.07-3.60)3.16 (0.85-11.60)2.79 (0.69-11.30)3.08 (0.61-15.20)2.24 (0.52-10.00 2.50 (0.57-11.40)1.75 (0.39-7.77)5.04 (0.90-28.30)1.59 (0.32-7.92)3.21 (0.45-22.7)NA3.30 (0.52-21.90)2.13 (0.38-11.80)3.13 (0.37-26.40)5.07 (0.64-39.00)5.49 (0.92-31.60)1.60 (0.25-10.10)3.68 (0.58-22.30)6.40 (1.57-25.30)3.40 (0.51-21.80)Vin3.30 (0.34-34.70)3.55 (0.73-22.40)0.57 (0.14-2.59)0.50 (0.13-2.17)0.56 (0.18-1.81)0.41 (0.09-2.11)0.45 (0.10-2.34)0.32 (0.08-1.55)0.92 (0.15-5.88)0.29 (0.06-1.52)0.58 (0.08-4.29)NA0.60 (0.09-4.14)0.39 (0.06-2.47)0.57 (0.07-4.89)0.93 (0.12-7.39)1.00 (0.17-5.97)0.29 (0.05-1.92)0.67 (0.11-4.29)1.15 (0.28-4.91)0.61 (0.10-4.08)0.18 (0.03-1.36)WBRT1.06 (0.15-9.99)0.52 (0.28-0.91)0.46 (0.21-0.93)0.51 (0.17-1.40)0.37 (0.17-0.78)0.41 (0.19-0.88)0.29 (0.11-0.70)0.83 (0.22-2.81)0.26 (0.08-0.75)0.53 (0.11-2.41)NA0.55 (0.13-2.26)0.35 (0.10-1.19)0.52 (0.08-2.88)0.84 (0.14-4.18)0.91 (0.23-3.16)0.26 (0.06-1.03)0.60 (0.14-2.32)1.06 (0.49-2.06)0.55 (0.13-2.25)0.17 (0.04-0.67)0.91 (0.17-4.04)PlaceboResults for PFS are shown in blue-colour cells, results for OS are in gray-color cells. Comparisons should be read from left to right and the estimate is in the cell in common between the column-defining drugs and the row-defining treatment. For PFS and OS, HRs (and 95% CI) less than 1 favour the column-defining treatment. To obtain HRs for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold and underscored. Abbreviations: Gef, gefitinib; Erlo, erlotinib; Ico, icotinib; Afa, afatinib; Dac, dacomitinib; Osi, osimertinib; Naq, naquotinib; Erlo+Bev, erlotinib+bevacizumab; Ona+Erlo, onartuzumab+erlotinib; Erlo+Tiv, erlotinib+tivantinib; Sun+Erlo, sunitinib+erlotinib; Gef+Peme, gefitinib+pemetrexed; Cil+Cet+Plat, cilengitide+cetuximab+platinum-based therapy; Cet+Bev+Plat, cetuximab+bevacizumab+platinum-based therapy; Cet+Plat, cetuximab+platinumrs   F G z{KLIJ'8I E"F"h"y"ǸhhKHOJQJaJo(%hh5>*KHOJQJ\aJ h /hhhKHOJQJaJ hNh,h3/hNB*CJKHOJQJ\aJph3h3/hN5CJOJQJaJfHo(q 8rsw   ) : K N Q b t Ff $$1$Ifa$gdgdN    ) : K N _ p   ' Ff $$1$Ifa$gd' 8 ; L ^ o    $ 5 F J [ l o Ff $$1$Ifa$gd   $ 5 F G X i z Ff> $$1$Ifa$gd !$5GXiz{ !3DUX[Ff% $$1$Ifa$gd[l~ !$'*-0369<?BEHFf. $$1$Ifa$gdHKL]n&7:=N`qFf@Ff]7 $$1$Ifa$gd %6GJ[l}FfH $$1$Ifa$gd#4EHK\n ,=Ff|Q $$1$Ifa$gd=@IL]n 1BTevyFf1Z $$1$Ifa$gd):KN_p}Ffb $$1$Ifa$gd 1BSdu%7Ffk $$1$Ifa$gd7IJ[l}*369J\mFf}FfPt $$1$Ifa$gd -0BSewFf $$1$Ifa$gd .?BSdu'8IZFfo $$1$Ifa$gdZ]n 0ARctFf$ $$1$Ifa$gd"Df@d   0 B T f x Ffٟ $$1$Ifa$gd !!-!>!O!`!q!!!!!!!!!! ""/"4"Ff $$1$Ifa$gd4"E"F"W"h"y"""""""""##&#7#H#Y#j#{#####*UFfFfC $$1$Ifa$gdy""""{####t%%\'T*U+U,U-U.U/U0U1U2U3U4U5U7U8U:U;U=U>UAUBUįăăăăxplplplplxhS4jhS4Uh-h`h-h`CJaJ%hhB*KHOJQJaJphU,h2;hB*CJKHOJQJaJo(ph)h2;hB*CJKHOJQJaJph h /h"hh5KHOJQJ\aJhhKHOJQJaJ%hh5>*KHOJQJ\aJ-based therapy; Erlo+Plat, erlotinib+platinum-based therapy; Mot+Plat, motesanib+platinum-based therapy; Plat, platinum-based therapy; Doc, docetaxel; Vin, vinorelbine; WBRT, whole-brain radiotherapy; PFS, progression-free survival; OS, overall survival; HR, hazard-ratio, CI, confidence interval.     *U+U,U-U.U[Gkd$$Ifl4;XD t644 lBayt $$1$Ifa$gdNkd$$Ifl4JXD t644 lBap yt.U/U0U1U2UaGkd$$Ifl4JXD t644 lBayt $$1$Ifa$gdGkdk$$Ifl48XD t644 lBayt2U3U4U6U7U9U:U4$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd<$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / BpytkdE$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd]N$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / BpytkdW$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd_$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd|h$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd1q$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkdy$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / BpytkdP$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkdo$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/  /  / / / Bpytkd$$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyt$$If!vh#v #vy#v #v#v #v #v #v ;#v {#v #v#v :V lX , t6,55555 5 5 5 5 555/ / / / / Bpytkdٶ$$IflX .9 $'+/48<@DHL~PTXDDDDDDDDDDDDDDDDDDDDDD , t6XXXX44 lBapyts$$If!vh#vX:V l4J t6+,5/ Bp ytf$$If!vh#vX:V l4; t6+,5/ Bytf$$If!vh#vX:V l48 t6+,5/ Bytf$$If!vh#vX:V l4J t6+,5/ Bytf$$If!vh#vX:V l4 t6+,5/ Byt-h`j 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nH sH tH R`R -cNormal $1$a$ CJKH_HaJmH nHsH tHDA`D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List L@L  0Header9r G$Pa$CJaJ66  0 Header CharCJaJB @B  0Footer9r G$a$CJaJ6!6  0 Footer CharCJaJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] '\ y"BU( ' [H=7Z 4"*U.U2UBU !"#$%&'+,-T # @H 0(  0(  B S  ?svFI $ @ H p|*2$&.0EGOQfhpr6@HJbluw3sX*~A$ ALt=2( /2;-h`-cWh _S43//N=+MRN@vvvv4\8@88@@8@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial;(SimSun[SO7.@ CalibriA$BCambria Math qhԵzGd99A?!%),.:;>?]}    & 0 2 3 : !6"000 0 0 0000006:>@DZ\^ =@\]^$([{  0 0 000000Y[];[9923QHX  $P2!xx lenovoDell 10Oh+'0X    ,8@HPlenovo Normal.dotmDell 105Microsoft Office Word@G@T@i՜.+,0 hp  admin9  Title  !"#$%&'()*+,-.0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry FkData /1TablewWordDocument?\SummaryInformation(DocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q